Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Swiss National Bank

Swiss National Bank lowered its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 4.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 923,000 shares of the company's stock after selling 43,800 shares during the period. Swiss National Bank owned approximately 0.24% of Moderna worth $38,378,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the company. Rakuten Securities Inc. raised its stake in shares of Moderna by 696.9% during the fourth quarter. Rakuten Securities Inc. now owns 7,499 shares of the company's stock valued at $312,000 after acquiring an additional 6,558 shares in the last quarter. Avantax Advisory Services Inc. bought a new stake in shares of Moderna during the fourth quarter valued at approximately $483,000. Farther Finance Advisors LLC raised its stake in shares of Moderna by 289.3% during the fourth quarter. Farther Finance Advisors LLC now owns 3,519 shares of the company's stock valued at $146,000 after acquiring an additional 2,615 shares in the last quarter. Moors & Cabot Inc. raised its stake in shares of Moderna by 3.6% during the fourth quarter. Moors & Cabot Inc. now owns 56,423 shares of the company's stock valued at $2,346,000 after acquiring an additional 1,954 shares in the last quarter. Finally, New Insight Wealth Advisors raised its stake in shares of Moderna by 4.4% during the fourth quarter. New Insight Wealth Advisors now owns 8,545 shares of the company's stock valued at $355,000 after acquiring an additional 358 shares in the last quarter. Institutional investors own 75.33% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on MRNA shares. Leerink Partners cut their price objective on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a report on Thursday, January 16th. Berenberg Bank lifted their price objective on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a report on Thursday, January 16th. Evercore ISI set a $50.00 price objective on shares of Moderna in a report on Friday, February 14th. Royal Bank of Canada reissued a "sector perform" rating and set a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Finally, Citigroup started coverage on shares of Moderna in a report on Thursday, March 13th. They set a "neutral" rating and a $40.00 price objective on the stock. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Moderna has an average rating of "Hold" and an average target price of $59.60.

Moderna Stock Performance

NASDAQ MRNA traded down $0.87 on Thursday, reaching $32.45. 5,608,807 shares of the company's stock traded hands, compared to its average volume of 6,572,052. The firm has a market cap of $12.52 billion, a price-to-earnings ratio of -3.50 and a beta of 1.86. The stock has a 50 day moving average price of $35.31 and a 200-day moving average price of $46.45. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.